(Brussels) “Active competition law enforcement, at EU and national level, in the pharmaceutical sector contributes to delivering more affordable medicines and more choice to patients and healthcare systems, and promotes further innovation”. These are, in brief, the findings of the report on “Competition enforcement in the pharmaceutical sector (2009-2017)”, published by the European Commission today: it provides an overview on the enforcement of antitrust and merger rules in the pharmaceutical sector and describes how competition law enforcement has contributed to improving European patients’ access to affordable and innovative essential medicines. According to the report, “unfair and abusive” practices and mergers of pharmaceutical companies can lead to higher prices for medicines and hinder pharmaceutical innovation. “Giving European patients and healthcare systems access to affordable and innovative medicines is one of Europe’s main challenges and objectives”, said Margrethe Vestager, European Commissioner in charge of competition policy. This “valuable work” carried out by competition authorities across Europe will remain a priority.